Article info

Original research
Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma

Authors

  • Runze Shang Department of Hepatobiliary Surgery, Xijing Hospital, Xian, Shaanxi, China Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA Department of General Surgery, The 910 Hospital, Quanzhou, Fujian, China PubMed articlesGoogle scholar articles
  • Xinhua Song Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Pan Wang Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA Collaborative Innovation Center for Agricultural Product Processing and Nutrition & Health, Beijing Vegetable Research Center, Beijing Academy of Agriculture and Forestry Sciences, Beijing, China PubMed articlesGoogle scholar articles
  • Yi Zhou Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA Department of Infectious Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China PubMed articlesGoogle scholar articles
  • Xinjun Lu Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA Department of Hepatic Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  • Jingxiao Wang School of Life Science, Beijing University of Chinese Medicine, Beijing, Beijing, China PubMed articlesGoogle scholar articles
  • Meng Xu Department of General Surgery, The Second Hospital of Xi'an Jiaotong University, Xi'an, China PubMed articlesGoogle scholar articles
  • Xinyan Chen Department of Pharmacy, Hubei University of Chinese Medicine, Wuhan, Hubei, China PubMed articlesGoogle scholar articles
  • Kirsten Utpatel Institute of Pathology, University of Regensburg, Regensburg, Bayern, Germany PubMed articlesGoogle scholar articles
  • Li Che Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA R&D Center, Legend Biotech USA Inc, Piscataway, New Jersey, USA PubMed articlesGoogle scholar articles
  • Binyong Liang Hepatic Surgery Center, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China PubMed articlesGoogle scholar articles
  • Antonio Cigliano Institute of Pathology, University of Regensburg, Regensburg, Bayern, Germany PubMed articlesGoogle scholar articles
  • Matthias Evert Institute of Pathology, University of Regensburg, Regensburg, Bayern, Germany PubMed articlesGoogle scholar articles
  • Diego F Calvisi Institute of Pathology, University of Regensburg, Regensburg, Bayern, Germany PubMed articlesGoogle scholar articles
  • Xin Chen Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Xin Chen, BTS, University of California San Francisco Medical Center at Parnassus, San Francisco, CA 94122, USA; xin.chen{at}ucsf.edu; Professor Diego F Calvisi, Institute of Pathology, University of Regensburg, Regensburg, Germany; Diego.Calvisi{at}klinik.uni-regensburg.de
View Full Text

Citation

Shang R, Song X, Wang P, et al
Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma

Publication history

  • Received January 21, 2020
  • Revised September 25, 2020
  • Accepted October 6, 2020
  • First published November 3, 2020.
Online issue publication 
August 06, 2021

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.